Effects of metoprolol treatment on a disintegrin metalloproteinase expression and extracellular matrix remodeling after myocardial infarction in rats

Chinese Medical Journal

Volumn 120, Issue 17, 2007, Pages 1549-1552

  Zhao, Juan ^a   Qu, Xiu Fen ^a   Zhao, Chun Yu ^b   Cao, Feng Lin ^a   Zhou, Tao ^c   Li, Wei Min ^a   Huang, Yong Lin ^a  

^a HARBIN MEDICAL UNIVERSITY   (China)

^b CHINA REHABILITATION RESEARCH CENTER   (China)

^c SUN YAT SEN UNIVERSITY   (China)

Author keywords

A disintegrin metalloproteinase; Extracellular matrix; Metoprolol; Myocardial infarction; Ventricular remodeling

Indexed keywords

ADAM 10; ADAM PROTEIN; COMPLEMENTARY DNA; DISINTEGRIN; METALLOPROTEINASE; METOPROLOL; RNA; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA CONVERTING ENZYME;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DNA SYNTHESIS; DRUG EFFECT; ENZYME LINKED IMMUNOSORBENT ASSAY; EXTRACELLULAR MATRIX; GENE EXPRESSION; HEART HEMODYNAMICS; HEART INFARCTION; HEART LEFT VENTRICLE FUNCTION; HEART VENTRICLE REMODELING; MALE; NONHUMAN; NUCLEOTIDE SEQUENCE; PROTEIN EXPRESSION; PROTEIN FUNCTION; RAT; RNA ISOLATION;

EID: 34848815607     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: 10.1097/00029330-200709010-00016     Document Type: Article

References (11)

1. Sun M, Dawood F, Wen WH, Chen M, Dixon I, Kirshenbaum LA, et al. Excessive tumor necrosis factor activation after infarction contributes to susceptibility of myocardial rupture and left ventricular dysfunction. Circulation 2004; 110: 3221-3228.
2. Manso AM, Elsherif L, Kang SM, Ross RS. Integrins, membrane-type matrix metalloproteinases and ADAMs: potential implications for cardiac remodeling. Cardiovasc Res 2006; 69: 574-584.
3. Feldman AM, McTiernan C. Is there any future for tumor necrosis factor antagonists in chronic heart failure? Am J Cardiovasc Drugs 2004; 4: 11-19.
4. Bennet AM, van Maarle MC, Hallqvist J, Morgenstem R, Frostegard J, Wiman B, et al. Association of TNF-alpha serum levels and TNFA promoter polymorphisms with risk of myocardial infarction. Atherosclerosis 2006; 187: 408-414.
5. Li JJ. Inflammation in hypertension: primary evidence. Chin Med J 2006; 119: 1215-1221.
6. Fedak PW, Moravec CS, McCarthy PM, Altamentova SM, Wong AP, Skrtic M, et al. Altered expression of disintegrin metalloproteinases and their inhibitor in human dilated cardiomyopathy. Circulation 2006; 113: 238-245.
7. Davis GE, Senger DR. Endothelial extracellular matrix biosynthesis, remodeling, and functions during vascular morphogenesis and neovessel stabilization. Circ Res 2005; 97: 1093-1107.
8. Ohtsu H, Dempsey PJ, Frank GD, Brailoiu E, Higuchi S, Suzuki H, et al. ADAM17 mediates epidermal growth factor receptor transactivation and vascular smooth muscle cell hypertrophy induced by angiotensin II. Arterioscler Thromb Vasc Biol 2006; 26: e133-137.
9. Communal C, Colucci WS. The control of cardiomyocyte apoptosis via the beta-adrenergic signalilig pathways. Arch Mal Coeur Vaiss 2005; 98: 236-241.
10. Sun YL, Hu SJ, Wang LH, Hu Y, Zhou JY. Effect of beta-blockers on cardiac function and calcium handling protein in post-infarction heart failure rats. Chest 2005; 128: 1812-1821.
11. Yan SH, Hu HS, Wang XL, Xing QC, Wang Q, Shi CW, et al. Effects of prolonged metoprolol treatment on neural remodeling and inducible ventricular arrhythmias after myocardial infarction in rabbits. Int J Cardiol 2006; 117: 317-322.